Xarelto

Pharma

Biosimilar competiton takes big bite out of Bayer's Eylea sales

Bayer is getting hit with full force by biosimilar competition for its eye disease treatment Eylea, which saw a 24% sales decline in the first quarter.

Kevin Dunleavy May 12, 2026 10:51am

Bayer's pharma division sees one more year of declining sales

Mar 4, 2026 11:35am

heart stop delay heart stop stoplight red light

NIH stops Xarelto arm of stroke trial due to safety, efficacy

Feb 10, 2026 4:04pm

Bayer stays positive on newer meds as pharma sales stagnate

Nov 12, 2025 11:46am

Bayer has laid off over 12K during Bill Anderson's tenure as CEO

Aug 6, 2025 11:37am

Bayer weathers LOE for Xarelto with success of Kerendia, Nubeqa

May 13, 2025 11:25am